Market Overview

Dan Nathan's iShares iBoxx $ High Yid Corp Bond (ETF) Trade

Share:
Dan Nathan's iShares iBoxx $ High Yid Corp Bond ETF Trade

On CNBC's Options Action, Dan Nathan spoke about a bearish options strategy in iShares iBoxx $ High Yid Corp Bond (ETF) (NYSE: HYG).

Related Link: Scott Bauer's Gilead Sciences Trade

Nathan explained that the ETF is trading close to its resistance and he thinks that it is going lower. He wants to make a bearish bet with a put calendar. Nathan wants to sell the August 84 put for $0.25 and buy the October 84 put for $1.45. The strategy would cost him $1.20. His trade is going to make money if the stock trades below $82.80 at the October expiration, but only if it stays above $84 at the August expiration.

Full ratings data available on Benzinga Pro.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com with the story link to let us know!

Posted-In: Analyst Color Broad U.S. Equity ETFs Options Markets Analyst Ratings Media Trading Ideas ETFs Best of Benzinga

 

Related Articles (HYG)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
EBAYMaintains34.5
WDCReiterates60.0
WATMaintains230.0
WRBMaintains56.0
MRVLMaintains29.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Barclays To GM: Dividend Play Or Growth Story, Pick One And Stick With It

Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences